Fred DumaisYesterday I did some whining and complaining to Fred about the share price, reverse splits, dilution, shorters, etc............. this was Freds response, hope it addresses some concerns, questions of other posters.......
That is a very good question Marty and one that I am afraid I can’t answer with certainty or a fair degree of precision. We only control what is related to the execution of our clinical programs and operations. On that front, we are moving forward full steam ahead with our plans. If we execute as I thing we will, it’s only a question of time before the share price starts to move again.
We will have to do a few things in the meantime, such as alleviate concerns related to financings. Fixing the balance sheet will obviously help as investors get nervous when there is less than 1 year of cash ahead. Getting our first product approved by the FDA will also help tremendously as it will de-risk the platform and demonstrate that we can take a protein from plasma and bring it all the way to market. This should take place later in 2017. In the meantime, we continue to work on potential partnerships and hope to be able to close some during this year.
If we execute as planned, the share price will have no choice but to adjust accordingly in my opinion.
Hope this helps and I hope to see you at the AGM in May
Best regards,
Fred